Summary:
1. Corcept Therapeutics received a regulatory rejection from the FDA for its hypertension medication, leading to a sharp decline in its share price.
2. Despite the setback, the company is determined to continue pursuing approval for the drug and plans to meet with FDA officials to explore potential next steps.
3. The FDA’s response marks a significant defeat for Corcept, as further clinical trials may be necessary for the drug to gain approval.
Rewritten Article:
As 2025 came to a close, Corcept Therapeutics faced a major setback when the FDA issued a complete response letter rejecting its hypertension medication, relacorilant. The news caused the California-based company’s stock price to plummet by over 50% in a single day, disappointing both the company and its shareholders.
The FDA’s decision was a blow to Corcept, as the regulator expressed concerns about the effectiveness of relacorilant despite it meeting the primary endpoint in a late-stage clinical trial. The medication targets hypertension secondary to hypercortisolism, a rare hormonal disorder also known as Cushing’s syndrome.
Despite this setback, Corcept remains determined to find a way to bring relacorilant to market. The company plans to engage in discussions with FDA officials to explore potential paths forward for the drug. However, any future success would likely require additional clinical trials, making the road to approval challenging for Corcept.
In the wake of the FDA’s rejection, Corcept must regroup and strategize its next moves carefully. The company’s commitment to advancing relacorilant underscores its dedication to addressing the unmet needs of patients with hypertension secondary to hypercortisolism. While the road ahead may be challenging, Corcept remains focused on advancing innovative treatments in the field of biotechnology.
